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N
anomedicine has made significant
advances because of the infusion of
sophisticated nanostructures in di-
agnostics and therapeutics. Understand-
ing the dynamics of nanomaterials in cells,
especially the nucleus, critical for nuclear
targeting and therapy remains largely an
underexplored field. Different types of nano-
materials such as gold, silver, silica, mag-
netic nanoparticles,14 polymer and lipo-
some nanoparticles,58 and quantum dots
(QDs)9,10 have been developed to target live
cells for drug or gene delivery for theranos-
tics. Most of the past studies have demon-
strated the potential of these nanomaterials
in cancer treatment but primarily in cancer
cell targeting or uptake studies and drug
delivery. A thorough understanding of the
intracellular fate in relation to the nucleus
and the efficacy of nuclear drug delivery has
not been explored. Nanoparticles of very
small size have been postulated to enter the
nucleus through the nuclear pore complex,
which is about 610 nm in diameter and
acts as the gateway for nucleo-cytoplasmic
exchange.11 Uptake of nanoparticles be-
yond this size can be triggered with the
aid of a nuclear localization signal (NLS).12
Gold nanoparticles functionalized with an
arginine-glycine-aspartic (RGD) peptide and
NLS peptide have been used for cancer cell
nuclear targeting.13 Most of the past studies
focus on receptor targeting while few on
nuclear targeting because of the challenges
in the nuclear delivery of nanoparticles. The
nucleus of eukaryotic cells contains a ma-
jority of the genetic materials in which DNA
replication and transcription occur. Hence
strategies for intracellular quantification of
nuclear materials will enhance our under-
standing of nuclear delivery and targeting
therapeutics.
Fluorescentnanoparticles, suchasQDs,have
beenwidely used for intracellular imaging due
to their intense fluorescence. However, the
toxicity of QDs limits its use in nanomedicine.14
Goldnanoclusters (AuNCs) of∼2nm in sizeare
attractive because of their strong fluorescence
emission which permits quantification of nu-
cleus targeting materials at single particle sen-
sitivity. To examine these particles, a single
wavelength source is sufficient for simul-
taneous excitation of nanoclusters of vary-
ing emission, similar to QDs.1517 Fluorescent
AuNCsarealsobiocompatibileandphotostable
* Address correspondence to
josephi@purdue.edu.
Received for review August 21, 2011




Recent advances in fluorescent metal nanoclusters have spurred tremendous interest in
nanomedicine due to the ease of fabrication, excellent biocompatibility, and, more
importantly, excellent wavelength-dependent tunability. Herein, we report our findings on
fluorescent BSA-protected gold nanoclusters (AuNCs), ∼2 nm in size conjugated with
Herceptin (AuNCs-Her), for specific targeting and nuclear localization in ErbB2 over-expressing
breast cancer cells and tumor tissue as a novel fluorescent agent for simultaneous imaging and
cancer therapy. More interestingly, we found that AuNCs-Her could escape the endolysosomal
pathway and enter the nucleus of cancer cells to enhance the therapeutic efficacy of Herceptin.
We elucidate the diffusion characteristics (diffusion time and number of diffusers) and
concentration of the fluorescing clusters in the nucleus of live cells. Our findings also suggest
that the nuclear localization effect of AuNCs-Her enhances the anticancer therapeutic efficacy
of Herceptin as evidenced by the induction of DNA damage. This study not only discusses a new
nanomaterial platform for nuclear delivery of drugs but also provides important insights on
nuclear targeting for enhanced therapy.
KEYWORDS: gold nanoclusters . nuclear nanomedicine . single particle
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and can serve as excellent bioimaging contrast agents
for nuclear nanomedicine, which has only been spar-
sely addressed.1820
Trastuzumab (Herceptin), a humanized monoclonal
antibody targeting the extracellular domain of ErbB-2
receptor, is over-expressed in 2530% of breast can-
cers and distant metastases.21 However, the response
rate to Herceptin has only been 735% in clinical
patients.22 A limiting factor in treatment efficacy en-
hancement is the lack of an effective drug delivery
vehicle to assist in the translocation of the drug from
the cytoplasm to the nucleus.23,24 The therapeutic
mechanism of Herceptin as reported reveals that cell
proliferation decreases due to an increase in the
frequency of DNA double strand breaks in the
nucleus.25 However, more recently, studies point to
the fact that nuclear localization sequence (NLS)-con-
jugated trastuzumab (Herceptin) could kill breast can-
cer cells that are resistant to trastuzumab by inducing
DNA damage, affirming the importance of developing
nuclear delivery strategies for effective therapy.26
Herein, we hypothesize that Herceptin-conjugated
AuNCs, that is, AuNCs-Herceptin (AuNCs-Her), could
facilitate effective passage of Herceptin through the
nuclear pore and into the nucleus to significantly
enhance the anticancer effect of the drug. Therefore,
fluorescent correlation spectroscopy (FCS) and fluores-
cence lifetime imaging (FLIM) were used in this study
to track the dynamics of nanoprobes at single particle
sensitivity. FCS is a noninvasive single particle fluores-
cence technique based on autocorrelation of tem-
poral behavior of fluorescence fluctuation. FCS analysis
provides information on the diffusion time, absolute
concentration of the diffusers, and binding kinetics and
opens a new direction for tracking the biochemical
pathway in intact cells and organs.27 FLIM could sepa-
rate the species based on differences in the exponen-
tial decay rate of fluorescence (lifetime),which is
independent of the local concentration of fluorescence
molecules and the excitation intensity.28 In this study,
we combine FCS with FLIM to report on the diffusion of
AuNCs-Her and its entry into the nucleus in live cell
conditions. An effective mode of cancer therapy could
constitute the specific delivery of high levels of ther-
apeutic agents to hypersensitive subcellular sites such
as the nucleus of tumor cells without affecting healthy
cells and tissues.29 Photothermal therapy with cell
surface targeting is an effective method for cancer
therapy.30 However, this method is limited by penetra-
tion depth of the laser (e.g., <400 μm for a two-photon
excitation31). In addition, only a few cells can be
illuminated at a time in a given focal volume.
RESULTS AND DISCUSSION
Characterization of AuNCs and Bioconjugated AuNCs-Her.
Biocompatible fluorescent AuNCs, ∼2 nm in size
(Figure 1a), were prepared according to the method
proposed by Xie et al.16 Its absorption and emission
spectra (Figure 1b) show that its characteristic surface
plasmon peak disappears and a strong bright near-
infrared peak emerges at 640 nm. The strong fluores-
cence of AuNCs was due to the d-band excitation
as reported.32 Figure 1c shows the scheme for the
Figure 1. (a) TEM image of the as-prepared AuNCs; (b) UVvis absorbance and fluorescent spectrum of AuNCs, and (c)
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conjugation of Herceptin to AuNCs. During synthesis,
bovine serum albumin (BSA) that formed on the outer
layer of AuNCs was carboxylated by glutaraldehyde
and glycine, to which amino groups bearing Herceptin
were functionalized through the EDC linkage.33 TEM
image further demonstrates that the as-prepared
AuNCs-Her (Figure S1 in Supporting Information) clus-
ters are distributed uniformly and no aggregates could
be noted. The size of the AuNCs-Her was calculated to
be ∼3.5 nm after the conjugation of Herceptin, an
increase of∼2.0 nm from the initial size of AuNCs. The
chemical conjugation was further confirmed by mon-
itoring the change in the diffusion time of naked
clusters (0.46 ms) and clusters conjugated with Her-
ceptin (0.73 ms) by fluorescence correlation spectro-
scopy (FCS). The increase in diffusion time observed
could be attributed to an increase in the molecular
weight of the gold clusters with andwithout Herceptin.
Cancer Cell and Tumor Tissue Targeting. SK-BR3 cells, a
human breast cancer cell over-expressing HER2 on the
cell membrane, were chosen as the target, and AuNCs-
Her and AuNCs were incubated with the cells for 4 h.
Figure 2 shows the confocal fluorescence images of the
clusters in cells. The left side of panel D (Figure 2) shows
emission from Lysosensor (400450 nm), whereas the
right shows emission from AuNCs (650720 nm). Due
to the specific interaction of Herceptin with ErbB-2
receptor, high uptake efficiency of the AuNCs-Her
probes (Figure 2A, left) was noted as evident from
the discrete bright spots, whichwas assumed to under-
go an ErbB2 receptor-mediated endocytosis. Past reports
have shown that nanoparticle endocytosis depends on
the cell type, clathrin dependence, and the size or the
shape of the nanoparticles.3436 Here, we found that
the uptake of AuNCs without the antibody was rare
compared to AuNCs-Her (Figure 2A, right) in ErbB-2
over-expressing SK-BR3 cells even after 4 h of
incubation. To further confirm targeting specificity,
AuNCs-Her probes were incubated with ErbB-2 under-
expressing MDA-MB-468 cells as control. Control ex-
periments show only an insignificant uptake, possibly
due to nonspecific interaction (Figure S2, left). The
targeting specificity of AuNCs-Her was further illu-
strated by comparing ErbB-2 receptor over-expressing
breast cancer tumor tissues (infiltrating duct carcinoma)
(Figure 2B, left) with normal tissues (Figure 2B, right).
Almost no signal was observed from the normal
tissues, while tumor tissues exhibited strong fluo-
rescence due to targeting, further demonstrating
that AuNCs-Her has strong specific binding with
ErbB-2 receptors.
Endosome Escape for AuNCs-Her to the Nucleus. Interest-
ingly, a strong bright spot was noted in Figure 2A (left),
which was attributed to the accumulation of AuNCs
specifically in the nucleus of cells. To further demon-
strate the localization of the probes, Lamina A antibody
was used as a nuclear envelop marker to specifically
stain the inner nuclear membrane. Fluorescence life-
time imaging (FLIM)was used to separate the envelope
and the inner regions based on their difference in
lifetime as fitted by exponential decay fitting functions.
Clear difference in the fluorescence lifetime of AuNCs
(1.5 ns) and Lamina A antibody labeled with Alexa350
(1.9 ns) was noted (Figure 2C), indicating the presence
of AuNCs in the nucleus. AuNCs were found to be
distributed throughout the cytoplasm as well as in the
chromosomal regions of the nucleus (Figure 2C, left).
Compared to cells incubatedwith bare AuNCs, only the
envelop marker could be visualized (Figure 2C, right).
Our previous studies using gold nanorods (AuNRs)
show that most of the Herceptin-conjugated AuNRs
are entrapped in the endolysosomal system with
minimal escape from the endosomes posing a major
barrier for effective drug delivery and release.37 Thus,
nanomaterials capable of endosomal escape might
have the ability to localize in the nucleus and could
Figure 2. (A) Confocal fluorescence intensity image of SK-BR3 cells incubated with AuNCs-Her (left) and AuNCs alone for 4 h
(right). (B) Confocal images of breast cancer tissue (left) and normal breast tissue (right) as control incubatedwith AuNCs-Her.
(C) FLIM of SK-BR3 cells stained by Lamin A antibody labeledwith Alexa350, indicating nuclear uptake of AuNCs-Her (left) and
AuNCs alone (right) incubated for 4 h as control. FLIM scale bar: 0 to 2 ns. (D) Endolysosomes of SK-BR3 cells incubated with
AuNCs-Her for 4 h and stained by lysosensor marker blue. From left to right: Emission from Lysosensor (400450 nm) and
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serve as effective drug delivery and therapeutic agents.
Experiments demonstrate that AuNCs are able to
escape the endosome and enter the nucleus to impart
therapy with high efficacy. Lysosensor was used to
stain the endosomes and lysosomes of live SK-BR3 cells
tomonitor uptake of AuNCs-Her after 4 h of incubation.
Confocal images show that a majority of AuNCs-Her
did not accumulate within the endosome (Figure 2D),
signifying their endosomal escaping ability. Super-
resolution images obtained by structured illumination
microscopy with 100 nm lateral resolution (ELYRA S.1,
Carl Zeiss Inc.) showed part of AuNCs-Her localizing in
the nucleus as indicated by discrete bright spots within
the nuclear envelop and other AuNCs-Her localizing in
the cytoplasm (Figure S3). As demonstrated through
our endosome labeling experiments, AuNCs showed
the capability of escaping from the endolysosomal
system. This provides an opportunity for some of the
AuNCs to freely diffuse through the nuclear pore
simply due to its ultrasmall size. This process is unlikely
to be mediated by specific transport protein since the
AuNCs are not conjugated with nuclear localization
sequence bearing peptides.
Dynamic Tracking of AuNCs-Her in the Nucleus of the Cells.
Transport of proteins into the nucleus is an essential
and important process in eukaryotic cells influencing
gene regulation. Having demonstrated that AuNCs-Her
could enter the nucleus, we attempt to determine the
dynamics of these nanoscale probes in the nucleus of
live cells using FCS. Herceptin-labeled with Alexa647
was first incubated with SK-BR3 cells for 4 h (control),
and its localization in cells was tracked by confocal
microscopy (the labeling of Alexa647 on Herceptin
and AuNCs was confirmed by monitoring the diffusion
time using FCS and fluorescence spectra, as shown in
Figure S4). It was found that Herceptin primarily local-
ized on the cell membranes and in specific intracellular
compartments as expected. In addition, free Herceptin
had very limited ability to pass through the nuclear
pore complex.38 However, single point FCS measure-
ments confirmed the presence of AuNCs-Her in the nu-
cleus of live SK-BR3 cells (Figure 3A) by monitoring the
diffusion timeandconcentration fromtheautocorrelation
plot. The autocorrelation curves of AuNCs-Her diffusion
in the nucleus could be well fitted with a single
component since a two-component free diffusion
model did not improve the quality of fit of the auto-
correlation functions of AuNCs diffusing in the nucleus
(Figure 3A). The inset in Figure 3A shows the FLIM of
live SK-BR3 cells after 4 h of incubationwithAuNCs-Her.
The yellow color represents the staining of the cell
membrane. It is well-known that ErbB2 is predomi-
nantly expressed on the cell surface. Due to the specific
interaction between Herceptin and ErbB2, it is clear
that particles are internalized while some could possi-
bly reside on the cell membrane even after 4 h of
incubation. Maxima entropy method FCS (MEMFCS)
was used to assess the diffusion of different species.
MEMFCS is particularly suitable for the analysis of
systems with heterogeneous diffusion time and does
not need a priori to be assigned for fitting the diffusion
time.39 The diffusion time of AuNCs-Her in the cyto-
plasm was found to be ∼0.8 ms (data not shown).
Interestingly, we found that the diffusion of AuNCs-Her
in the nucleus has two distinct peaks: one at ∼0.5 ms
and the other ∼10 ms (Figure 3B). The faster diffusers
could be attributed to the diffusion of AuNCs-Her in the
nucleus with minor obstacles. The slower diffusers are
possibly due to the interaction of the nanoclusters with
nuclear proteins or chromatin structures or the com-
plexity of traversing the nuclear matrix. The exact
mechanism of the interaction between AuNCs and
nuclear protein and its trajectory could be the subject
for future explorations. The formation of larger aggre-
gates in the nucleus is unlikely since no significant
intermittent spikes could be found in the fluorescence
fluctuation data. In addition to the diffusion dynamics,
the absolute concentration of AuNCs-Her in the nu-
cleus of live cells was also estimated by FCS. From the
amplitude of the autocorrelation function, the concen-
tration of AuNCs-Her in the nucleus was estimated to
be 510 nM. This concentration was found to be
sufficient to induce DNA damage and apoptosis.
DNA Damage and Apoptosis of AuNCs-Her to the Cells. Here
we show that AuNCs-Her could escape the endosome/
lysosome pathway and penetrate the nuclear pore
Figure 3. (A) Typical autocorrelation curve (solid squares) of AuNCs-Her diffusing inside the nucleus fitted with two
components (black solid line). Inset is the image of SK-BR3 cells incubated with AuNCs-Her-Alexa647 for 4 h. (B) MEMFCS
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complex to enhance the therapeutic efficacy. Experi-
ments indicate that AuNCs-Her has the potential to
induce enhanced DNA damage and apoptosis in SK-
BR3 cells because of its nuclear targeting ability.
Hoechst 33258 binds preferentially to the A-T base
pairs from the side of theminor groove of the DNA and
can be used to visualize the apoptotic body formation
and nuclear changes which are characteristic of apop-
tosis. Our results show that both Herceptin and AuNCs-
Her could induce apoptosis while apoptosis could
not be observed in cells treated with bare AuNCs
(Figure 4A). Early DNA damage was signified by the
phosphorylation of γ-H2A.X using appropriate anti-γ-
H2A.X targeting antibodies. To further confirm our
findings, cells were probed using the phosphorylated
form of H2A.X (γ-H2A.X) antibody which signals the
initial response to double-stranded break (DSB).4042
FLIM indicated that almost all of the cells cultured with
AuNCs-Her had specific fluorescence staining, repre-
senting DNA damage (Figure 4D). In contrast, only a
small amount of cells treated with Herceptin alone
shows DNA damage under the same condition to
indicate that the antitumor effect of AuNCs-Her is
much higher than the treatment with Herceptin alone
(Figure 4E). Quantification of apoptosis positive cells as
a percentage of the total number of cells revealed that
only 35%of the cells treatedwithHerceptin underwent
apoptosis due toDNAdamage compared to 95%of the
AuNCs-Her (Figure 4F) treated cells (p < 0.05, n = 500).
Cell death experiments (MTT assay) shown in Figure S5
further confirm that the antitumor activity of Herceptin
could be enhanced by AuNCs due to nuclear targeting
of AuNCs.
CONCLUSION
Collectively, our results demonstrate that fluores-
cent metal nanoclusters (AuNCs) conjugated with a
targeting ligand (e.g., Herceptin in our model) possess
high targeting specificity and nuclear localization cap-
ability. These fluorescing probes can be used for
simultaneous imaging and enhanced cancer therapy
because of its ability to induce nuclear damage. Im-
portantly, we found that the endocytosed AuNCs-Her
could escape the endolysosomal pathway and has the
ability to penetrate the nucleus possibly due to its small
size effect. By employing FCS, the diffusion character-
istics and concentration of AuNCs-Her in the nucleus
was also elucidated. Our experiments further indicated
that the therapeutic effect of Herceptin could be
significantly enhanced possibly due to the nuclear
targeting ability of AuNCs-Her and its endolysosomal
escape, opening a new route to nuclear nanomedicine.
MATERIALS AND METHODS
Chemical Reagents. Hydrogen tetrachloroaurate (III) trihydrate
(HAuCl4 3 3H2O, 99%), BSA, glutaraldehyde, glycine, sodium
borohydride, and N-(3-(dimethylamino)-propyl)-N0-ethylcarbo-
diimide (EDC) were obtained from Sigma-Aldrich Chemical Co.
and used without further purification. All of the water used was
purified with Milli-Q plus system (Millipore Co.), and the resis-
tivity was kept to over 18 MΩ 3 cm.
Synthesis of Gold Nanoclusters. Gold nanoclusters (AuNCs) were
synthesized according to the method proposed by Xie et al.16
Briefly, 5 mL of 10mM aqueous chloroauric acid solution (37 C)
was added to 5 mL of 50 mg/mL BSA solution (37 C) under
vigorous stirring. Two minutes later, 0.5 mL of 1 M NaOH
Figure 4. Fluorescence images show the apoptosis induced by AuNCs alone (A), AuNCs-Her (B), and Herceptin (C) by staining
the nucleuswith Hoechst 33258 (excited by UV light and the emission is 460 nm). Fluorescence lifetime imaging (FLIM) shows
DNA damage of SK-BR3 cells induced by AuNCs-Her (D) and Herceptin alone (E) indicated by the bright yellow dots.
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solution was introduced, and the mixture was incubated at
37 C for 12 h. The color of the solution changed from light
yellow to light brown and then to deep brown. Excess salt was
removed through dialysis.
Characterization and Functionalization of AuNCs by Herceptin. As-
prepared AuNCs were characterized by UVvis absorption
spectroscopy using a Jasco V570 UV/visible/NIR spectrophot-
ometer (Jasco, Inc., Easton, MD) in the 200900 nmwavelength
range. Fluorescent emission spectra were obtained using the
Cary fluorescent spectrometer.
The functionalization of AuNCs with Herceptin was carried
out according to the method reported by Sun et al.33 Glutar-
aldehyde was first introduced along with the AuNCs to form the
cross-linked organic layer around AuNCs. The extra aldehyde
functional groups on the AuNCs' surface were removed by
treatment with glycine or sodium borohydride. Since most of
the surface amino groups on the BSA are removed in this
process, AuNCs carried a net negative charge from the car-
boxylic acid groups. The activation of carboxylic acid groups on
the BSA molecule was achieved by treatment with EDC. Excess
EDC was removed by centrifugation using the cutoff tube, and
the resulting O-acylisorurea intermediates are reacted with
amino groups from Herceptin to form amide bonds between
the encapsulation layer and Herceptin.
Since excess chemicals will be removed by centrifugation
using the cutoff tube, contribution from the chemicals to the
cell death is assumed to be negligible.
Cell Culture. SK-BR3 cells and MDA-MB-468 were maintained
in RPMI medium 1640 (Sigma-Aldrich) supplemented with 10%
fetal bovine serum (Sigma-Aldrich) and 1% penicillin/strepto-
mycin (Sigma-Aldrich). Cultures were maintained at 37 C and
5% CO2 atmosphere. For living-cell fluorescence microscopy
studies, cells were seeded onto sterilized No. 1 coverslip (VWR
International, Batavia, IL) and placed inside a 12-well plate. After
the cells reached 80% confluence, they were incubated with
AuNCs, Herceptin, or AuNCs-Her at 37 C and washed with
minimum essential medium (MEM) three times. The culture was
kept active, and the cells were taken out from the incubator for
measurements at different time points (4 and 16 h) when
needed.
Tissue Treatment. Breast tumor tissues and the normal tissues
were treated according to the following protocol.
(a) Deparaffinization and hydration. Incubate the tissue in a
dry oven at 60 C for 1 h, dewax slides in freshly prepared
xylene for 4 min five times, and slides were then
hydrated in 100, 95, and 75% ethanol for 3 min twice.
The slides were then immersed in tap water for 5 min.
(b) Antigen retrieval: 200300 mL of H2O was added in a
rice cooker and allowed to boil for ca. 10 min. Next, the
slides were placed inside the bottle filled with antigen
retrievel buffer, incubated for 20min, then rinsed in cold
tap water for 35 min.
(c) Immerse slide in H2O2 for 6 min to reduce auto-
fluoresence.
(d) Wash the slides in 0.025%Triton X-100 PBS for 3 5min.
(e) Incubate the slides with blocking serum for 30 min to
blot excess serum from section. Incubate the slides with
AuNCs-Her at 4 C overnight. Wash the slide in PBS for
3 10min afterwhich the samples are ready for imaging.
Endosomal Escape. To more clearly reveal the mechanism of
AuNCs transfecting the nucleus of the cells, endosomal escape
study was carried out. After the incubation of AuNCs-Her with
cells for 4 h, cells were stained with endosome escape marker
(Lysosensor) for 30min. After washing with PBS three times, the
cells were imaged by confocal fluorescence microscopy.
Nuclear Envelope. After incubation of the AuNCs, AuNCs-Her
with SK-BR3 cells, cells on coverslips were fixed in 4% parafor-
maldehyde for 30 min, washed in PBS for 3  10 min, permea-
bilized for 10 min in 0.25% Triton X-100, and blocked in PBST
with 1% BSA for 30 min at room temperature. The coverslips
were incubated with the nuclear envelope marker (Lamin A
antibody; Abcam, ab2559) for 1 h at room temperature or 4 C
overnight, washed in PBS for 3  10 min, and incubated with
Alexa350-conjugated goat anti-rabbit secondary antibody
(Invitrogen) for 1 h at room temperature. Cells were then
washed in PBS for 3 10 min and then imaged by multiphoton
microscopy.
DNA Damage and Apoptosis. DNA double-strand breaks (DSBs)
in cancer cells incubated with AuNCs were verified using a
fluorescently labeled antibody specific for the phosphorylated
form of H2AX (γ-H2AX). Discrete nuclear foci can be visualized
at the sites of DSBs. After the incubation of SK-BR3 cells with
AuNCs, Herceptin, and AuNCs-Her, cells on coverslips were fixed
in 4%paraformaldehyde for 30min, washed in PBS for 3 10min,
permeabilized for 10 min in 0.25% Triton X-100, and blocked in
PBST with 1% BSA for 30 min at room temperature. The cover-
slips were incubated with anti-γ-H2A.X antibody (Bethyl La-
boratories, Inc.) for 1 h at room temperature or 4 C overnight,
washed in PBS for 3  10 min, and incubated with Alexa350-
conjugated goat anti-rabbit secondary antibody (Bethyl Labora-
tories, Inc.) for 1 h at room temperature. The cells were then
washed in PBS for 3 10 min and then imaged by multiphoton
microscopy.
After incubation of SK-BR3 cells with AuNCs, Herceptin, or
AuNCs-Her, the cells were fixed and stained by Hoechst 33258
dye to test for apoptosis.
MTT Assay. SK-BR 3 cells were seeded in a 96-well plate at a
density of 104 cells per well in a 100 μL volume. Cells were
further maintained at 37 C for 24 h after treatment with AuNCs,
Herceptin, or AuNCs-Her. Cell viability was then determined
using an MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide) assay (MTT cell growth assay kit, Chemicon, USA).
The AuNC-treated cells were incubated with the MTT reagent
for 4 h (viable cells are capable ofmetabolizing theMTT reagent,
while dead cells are not), and 100 μL of DMSO was added to
each well and incubated for 30 min, and the absorbance at
570 nmwas read. Each concentration was repeated in triplicate,
and the results are expressed as percentages.
Antibody Labeling. Herceptin was labeled with AlexaFluor647
monoclonal antibody labeling kit (Invitrogen) according to
manufacturer's instructions. Free fluorophores were removed
using a spin filter (MWCO 10 kDa, KPL). Fluorescence correlation
spectroscopy (FCS) was performed to confirm antibody labeling
based on the difference in diffusion time between free fluor-
ophores and labeled antibody as shown in Figure S4.
Fluorescence Lifetime Imaging. Fluorescence lifetime images
were acquired using the Microtime 200 system (Picoquant
Gmbh, Germany) fitted with picosecond lasers. Further details
of the instrumentation can be found elsewhere.37
The fluorescence lifetime was obtained by fitting the TCSPC




Ri exp  tτi
 
(1)
where τi denotes the lifetime with amplitudes Ri. The values of
τi and Ri were obtained through nonlinear least-squares fitting
using the SymphoTime software (PicoQuant).
FCS and MEMFCS. The autocorrelation curve of fluorophore
diffusing in solution was fitted to a 3D diffusion model using
one or two components with the SymphoTime software












where Ni and τDi denote the number of fluorescent molecules
in the detection volume and diffusion time of component
i, respectively. The parameter κ and the lateral diffusion coeffi-
cient D can be obtained from
k ¼ z0
w0





Here, κ is defined as the ratio of the axial beam size z and radiusω
of the laser, and τD denotes the diffusion time of the fluorophore.
MEMFCS (maximum entropy method analysis of fluo-
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S is defined as S = ∑ipiIn(pi), where pi = Ri/∑Ri.
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with AuNRs-Her incubation. Figure S3 shows the super-resolu-
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jugated with Herceptin-Alexa647 and absorption and fluores-
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